<DOC>
	<DOCNO>NCT01532518</DOCNO>
	<brief_summary>The present pilot study aim obtain preliminary data effect three ascend oral dose level nepadutant relief symptom associate feed intolerance . In addition , assessment drug exposure ( PK assessment ) provide additional information dose-effect relationship , thus support dose selection dose schedule future study .</brief_summary>
	<brief_title>Preliminary Efficacy , Safety Pharmacokinetics Study Nepadutant Infant With Feeding Intolerance</brief_title>
	<detailed_description>Feeding intolerance transient neuro-developmental phenomenon affect 25 % 40 % infant toddler , peak 6 week age . Feeding problem include mainly vomit , slow feeding , refusal eat colic . Current non pharmacological intervention ( e.g . message , restriction maternal diet breast-feeding infant ) pharmacological treatment ( simethicone , antimuscarinic drug antiacid ) largely unsatisfactory . Nepadutant postulate therapeutic effect infant colic since reverts exaggerate intestinal motility sensitivity induce different stimuli activation neurokinin-2 receptor , without interferring physiological gastrointestinal transit . This phase IIa study design test participant infant two three oral dos nepadutant order measure blood level , safety efficacy dose level give 7 concecutive day . The experimental clinical phase encompass follow period : - Screening period ( study medication ) , last approximately 7 day prior randomization - Treatment period , last fourteen day ( 7 day fore dose ) daily administration - A safety follow-up visit , approximately four week start treatment .</detailed_description>
	<mesh_term>MEN 11420</mesh_term>
	<criteria>Infants clinical diagnosis feed intolerance . Age â‰¤ 6 month enrolment . Normal growth . Infants refrain use erythromycin , metoclopramide , antihistaminic drug , proton pump inhibitor ( PPIs ) , antacid , antimuscarinic drug , simethicone dimethicone 1 week prior randomization end study . Any clinically relevant event ( exclude relevant condition study ) occur within one week prior randomization . Any pharmacological treatment start within one week prior randomization . Infants change diet ( i.e . wean ) perform within one week prior randomization plan study period .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Feeding intolerance</keyword>
	<keyword>Infant</keyword>
	<keyword>tachykinin antagonist</keyword>
	<keyword>Infant colic</keyword>
	<keyword>Nepadutant</keyword>
</DOC>